Click on a filter below to refine your search. Remove a filter to broaden your search.
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
THe one-year mortality following major surgery increased for adults aged 65 years or older with frailty or probable dementia.
Medicare spending was higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment.
Immediate and lasting reductions were seen in the share of patients receiving hospice care with the Alzheimer’s disease and related dementia code.
The percentage of older U.S. decedents with a diagnosis of Alzheimer’s disease and related dementias increased significantly from 2004 to 2017.
New premium will be $170.10 a month, and the $21.60 boost is the biggest increase ever in dollar amount, but not in percentage terms
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
Patients receiving thick versus thin liquids were less likely to be intubated and more likely to have respiratory complications.
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.